Relaxin for Treatment of Acute Heart Failure: Making the Case for Treating Targeted Patient Profiles

摘要: Patients presenting with acute heart failure (AHF) represent a heterogeneous population respect to demographics, clinical profiles, and precipitating factors. Despite this, most trials have treated the study as homogeneous group in an attempt achieve adequate statistical power for endpoint analysis. This approach has proven be of little value development new agents treatment AHF. By contrast, phase III trial relaxin focused on subset AHF patients who were normotensive or hypertensive had moderate renal impairment. The patients, primarily from Eastern Europe, represented that would expected less genetic variability than populations larger multinational trials. A design targeting specific patient profiles should considered future investigate therapies compare effectiveness existing therapies.